• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of research projects submitted to the 2009 calling of the Fundacio La Marato de TV3. Rare diseases]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of the research projects submitted to the 2010 call for topics of la Fundació La Marató de TV3. Acquired spinal cord and brain injuries]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessments tools for risk prediction of cardiovascular diseases]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Assistance at normal childbirth. Guide for pregnant women, future parents, as well as their partners and relatives]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Assisted reproduction]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assistive technology – digital tools that involve social stimulation for mental health in later life. An evidence map]]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Atazanavir/cobicistat (Evotaz®) in HIV infection]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Addendum to Commission A19-81]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with nab-paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2017     Basque Office for Health Technology Assessment (OSTEBA) [ATOMs – Adjustable Transobturator Male System. Device for urinary incontinence]
2008     Committee for New Health Technology Assessment (CNHTA) [ATP7A gene, mutation analysis]
2008     Committee for New Health Technology Assessment (CNHTA) [ATP7A gene, mutation[sequencing]]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [AUDIT ONCOrisk: Quality of the information in the study about digestive oncological surgery results]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Auditive implants: concept, indications and appropriate use]
2009     Committee for New Health Technology Assessment (CNHTA) [Auditory cortex stimulation]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Auricular acupuncture for narcotic dependency]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Autism spectrum disorder: scientific knowledge about the detection, diagnosis and treatment]
2018     Haute Autorite de sante (HAS) [Autism spectrum disorder: Warning signs, detection, diagnosis and assessment in children and adolescents]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Autism treatment with orthomolecular therapy]
2010     Committee for New Health Technology Assessment (CNHTA) [Autofluorescence image(endoscopy)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2007     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Autologous blood donations]
2009     Committee for New Health Technology Assessment (CNHTA) [Autologous blood injection]
2008     Committee for New Health Technology Assessment (CNHTA) [Autologous bone marrow cell infusion for advanced liver cirrhosis]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Autologous chondrocyte implantion. An updated systematic review and tutelage use extension]
2015     Norwegian Institute of Public Health (NIPH) [Autologous hematopoietic stemcell transplantation (HSCT) for multiple sclerosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Autologous lymph node transfer for lymphedema secondary to breast cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [Autologous noncultured epidermal cellular transplantation]
2011     Committee for New Health Technology Assessment (CNHTA) [autologous platelet rich plasma application]
2010     Committee for New Health Technology Assessment (CNHTA) [Autologous platelet rich plasma application]
2021     Norwegian Institute of Public Health (NIPH) [Autologous stem cell transplantation for multiple sclerosis : rapid scoping review]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Automated reading methods of uterine cervical cytology]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avacopan (severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (advanced systemic mastocytosis) - Assessment according to §35a (para. 1., sentence 11)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Avastin in ophthalmology]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Avastin® for age-related macular degeneration]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (urothelial carcinoma) - Addendum to Commission A21-23]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Azacitidine (Vidaza) for the treatment of myelodysplastic syndromes]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Azacitidine in the treatment of high-risk myelodysplastic syndrome]
2009     Committee for New Health Technology Assessment (CNHTA) [BAALC gene mRNA, quantitative [real-time RT-PCR]]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction - German short version and update of the correspondent EUnetHTA assessment]
2015     Andalusian Health Technology Assessment Area (AETSA) [Balloon eustachian tuboplasty for the treatment of eustachian tube dysfunction]
2009     Committee for New Health Technology Assessment (CNHTA) [Balloon tamponade for postpartum hemorrhage]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery as treatment for obesity in subjects over 65 years old]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bariatric surgery in diabetic type 2 patients with CMI at or above 30 kg/m2]
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery to treat obesity with a body mass index (BMI) less than 40 kg/m2]
2008     The Regional Health Technology Assessment Centre (HTA-centrum) [Bariatric surgery]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Baricitinib in COVID-19 patients]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (pulmonary multidrug-resistant tuberculosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (pulmonary multidrug-resistant tuberculosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Behaviour therapy for obesity treatment considering approved drug therapy]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Behaviour therapy for obesity treatment considering approved drug therapy]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Behavioural and skill-based early interventions in children with autism spectrum disorders]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belatacept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belatacept: addendum to Commission A15-25]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Belimumab for the treatment of Systemic Lupus Erythematosus]